BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 29755672)

  • 1. Inhibition of mTOR complex 2 restrains tumor angiogenesis in multiple myeloma.
    Lamanuzzi A; Saltarella I; Desantis V; Frassanito MA; Leone P; Racanelli V; Nico B; Ribatti D; Ditonno P; Prete M; Solimando AG; Dammacco F; Vacca A; Ria R
    Oncotarget; 2018 Apr; 9(29):20563-20577. PubMed ID: 29755672
    [TBL] [Abstract][Full Text] [Related]  

  • 2. RICTOR/mTORC2 affects tumorigenesis and therapeutic efficacy of mTOR inhibitors in esophageal squamous cell carcinoma.
    Lu Z; Shi X; Gong F; Li S; Wang Y; Ren Y; Zhang M; Yu B; Li Y; Zhao W; Zhang J; Hou G
    Acta Pharm Sin B; 2020 Jun; 10(6):1004-1019. PubMed ID: 32642408
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Regulation of endothelial cell proliferation and vascular assembly through distinct mTORC2 signaling pathways.
    Wang S; Amato KR; Song W; Youngblood V; Lee K; Boothby M; Brantley-Sieders DM; Chen J
    Mol Cell Biol; 2015 Apr; 35(7):1299-313. PubMed ID: 25582201
    [TBL] [Abstract][Full Text] [Related]  

  • 4. mTORC2 promotes type I insulin-like growth factor receptor and insulin receptor activation through the tyrosine kinase activity of mTOR.
    Yin Y; Hua H; Li M; Liu S; Kong Q; Shao T; Wang J; Luo Y; Wang Q; Luo T; Jiang Y
    Cell Res; 2016 Jan; 26(1):46-65. PubMed ID: 26584640
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hypoxia-induced endothelial proliferation requires both mTORC1 and mTORC2.
    Li W; Petrimpol M; Molle KD; Hall MN; Battegay EJ; Humar R
    Circ Res; 2007 Jan; 100(1):79-87. PubMed ID: 17110594
    [TBL] [Abstract][Full Text] [Related]  

  • 6. mTOR has a developmental stage-specific role in mitochondrial fitness independent of conventional mTORC1 and mTORC2 and the kinase activity.
    Kalim KW; Zhang S; Chen X; Li Y; Yang JQ; Zheng Y; Guo F
    PLoS One; 2017; 12(8):e0183266. PubMed ID: 28813526
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cytoplasmic and nuclear distribution of the protein complexes mTORC1 and mTORC2: rapamycin triggers dephosphorylation and delocalization of the mTORC2 components rictor and sin1.
    Rosner M; Hengstschläger M
    Hum Mol Genet; 2008 Oct; 17(19):2934-48. PubMed ID: 18614546
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Raptor-rictor axis in TGFbeta-induced protein synthesis.
    Das F; Ghosh-Choudhury N; Mahimainathan L; Venkatesan B; Feliers D; Riley DJ; Kasinath BS; Choudhury GG
    Cell Signal; 2008 Feb; 20(2):409-23. PubMed ID: 18068336
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Both mTORC1 and mTORC2 are involved in the regulation of cell adhesion.
    Chen L; Xu B; Liu L; Liu C; Luo Y; Chen X; Barzegar M; Chung J; Huang S
    Oncotarget; 2015 Mar; 6(9):7136-50. PubMed ID: 25762619
    [TBL] [Abstract][Full Text] [Related]  

  • 10. IKK interacts with rictor and regulates mTORC2.
    Xu Y; Lai E; Liu J; Lin J; Yang C; Jia C; Li Y; Bai X; Li M
    Cell Signal; 2013 Nov; 25(11):2239-45. PubMed ID: 23872070
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Two distinct mTORC2-dependent pathways converge on Rac1 to drive breast cancer metastasis.
    Morrison Joly M; Williams MM; Hicks DJ; Jones B; Sanchez V; Young CD; Sarbassov DD; Muller WJ; Brantley-Sieders D; Cook RS
    Breast Cancer Res; 2017 Jun; 19(1):74. PubMed ID: 28666462
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A HGF/cMET autocrine loop is operative in multiple myeloma bone marrow endothelial cells and may represent a novel therapeutic target.
    Ferrucci A; Moschetta M; Frassanito MA; Berardi S; Catacchio I; Ria R; Racanelli V; Caivano A; Solimando AG; Vergara D; Maffia M; Latorre D; Rizzello A; Zito A; Ditonno P; Maiorano E; Ribatti D; Vacca A
    Clin Cancer Res; 2014 Nov; 20(22):5796-807. PubMed ID: 25212607
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The inhibition of MAPK potentiates the anti-angiogenic efficacy of mTOR inhibitors.
    Dormond-Meuwly A; Roulin D; Dufour M; Benoit M; Demartines N; Dormond O
    Biochem Biophys Res Commun; 2011 Apr; 407(4):714-9. PubMed ID: 21439267
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ablation in mice of the mTORC components raptor, rictor, or mLST8 reveals that mTORC2 is required for signaling to Akt-FOXO and PKCalpha, but not S6K1.
    Guertin DA; Stevens DM; Thoreen CC; Burds AA; Kalaany NY; Moffat J; Brown M; Fitzgerald KJ; Sabatini DM
    Dev Cell; 2006 Dec; 11(6):859-71. PubMed ID: 17141160
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rictor regulates MMP-9 activity and invasion through Raf-1-MEK-ERK signaling pathway in glioma cells.
    Das G; Shiras A; Shanmuganandam K; Shastry P
    Mol Carcinog; 2011 Jun; 50(6):412-23. PubMed ID: 21557327
    [TBL] [Abstract][Full Text] [Related]  

  • 16. SIN1, a critical component of the mTOR-Rictor complex, is overexpressed and associated with AKT activation in medullary and aggressive papillary thyroid carcinomas.
    Moraitis D; Karanikou M; Liakou C; Dimas K; Tzimas G; Tseleni-Balafouta S; Patsouris E; Rassidakis GZ; Kouvaraki MA
    Surgery; 2014 Dec; 156(6):1542-8; discussion 1548-9. PubMed ID: 25456951
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rapamycin regulates the phosphorylation of rictor.
    Akcakanat A; Singh G; Hung MC; Meric-Bernstam F
    Biochem Biophys Res Commun; 2007 Oct; 362(2):330-3. PubMed ID: 17707343
    [TBL] [Abstract][Full Text] [Related]  

  • 18. LST8 level controls basal p70 S6 kinase and Akt phosphorylations, and mTORC1 and mTORC2 negatively regulate each other by competing for association with LST8.
    Kikuchi T; Zhang J; Sakoda H; Koketsu Y; Fujishiro M; Kushiyama A; Nakatsu Y; Kamata H; Inoki K; Takahashi S; Kurihara H; Hideki K; Oka Y; Asano T
    Obes Res Clin Pract; 2012; 6(3):e175-262. PubMed ID: 24331524
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Biochemical, cellular, and in vivo activity of novel ATP-competitive and selective inhibitors of the mammalian target of rapamycin.
    Yu K; Toral-Barza L; Shi C; Zhang WG; Lucas J; Shor B; Kim J; Verheijen J; Curran K; Malwitz DJ; Cole DC; Ellingboe J; Ayral-Kaloustian S; Mansour TS; Gibbons JJ; Abraham RT; Nowak P; Zask A
    Cancer Res; 2009 Aug; 69(15):6232-40. PubMed ID: 19584280
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dramatic suppression of colorectal cancer cell growth by the dual mTORC1 and mTORC2 inhibitor AZD-2014.
    Huo HZ; Zhou ZY; Wang B; Qin J; Liu WY; Gu Y
    Biochem Biophys Res Commun; 2014 Jan; 443(2):406-12. PubMed ID: 24309100
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.